Personalized mRNA cancer vaccine shows promise in extending lifespan in melanoma trial
(NEW YORK) -- Merck and Moderna announced Wednesday that a personalized mRNA-based cancer vaccine succeeded in a large, late-stage trial among high-risk patients with... Read More.


